Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017

  • ID: 4330538
  • Report
  • Region: Global
  • 39 Pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • RaQualia Pharma Inc
  • Yuhan Corp
  • MORE
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape.

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in your upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea. The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abide Therapeutics Inc
  • RaQualia Pharma Inc
  • Yuhan Corp
  • MORE
Introduction

Functional (Non Ulcer) Dyspepsia - Overview

Functional (Non Ulcer) Dyspepsia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development

Abide Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

RaQualia Pharma Inc

Yuhan Corp

Zeria Pharmaceutical Co Ltd

Functional (Non Ulcer) Dyspepsia - Drug Profiles

5-BIOP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acotiamide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-4005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mosapride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00201894 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-12852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Functional (Non Ulcer) Dyspepsia - Dormant Projects

Functional (Non Ulcer) Dyspepsia - Discontinued Products

Functional (Non Ulcer) Dyspepsia - Product Development Milestones

Featured News & Press Releases

Dec 14, 2016: Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia

Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia

Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Functional (Non Ulcer) Dyspepsia - Pipeline by Abide Therapeutics Inc, H2

Functional (Non Ulcer) Dyspepsia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2

Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc, H2

Functional (Non Ulcer) Dyspepsia - Pipeline by Yuhan Corp, H2

Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H2

Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2

Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2

List of Figures:

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abide Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Yuhan Corp
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll